A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

Giovanni Palladini, Paolo Milani, Andrea Foli, Marco Basset, Francesca Russo, Stefano Perlini, Giampaolo Merlini

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial,weassessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, alkylators, and other immunomodulatory drugs. Twenty-eight patients were enrolled. Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity. The remaining patients received 4mg/d. Pomalidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or 40 mg. Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and infection. Hematologic response was observed in 68% of patients (very good partial response or complete response in 29%), as well as improved survival. Median timetoresponsewas1month.PDexisarapidly active regimen and improves survival in responding, heavily pretreated patients with AL amyloidosis.

Original languageEnglish
Pages (from-to)2120-2123
Number of pages4
JournalBlood
Volume129
Issue number15
DOIs
Publication statusPublished - Apr 13 2017

Fingerprint

Proxy
Amyloidosis
Dexamethasone
Light
Survival
Salvaging
Alkylating Agents
Therapeutics
Salvage Therapy
Pharmaceutical Preparations
Toxicity
Fluids
pomalidomide
Safety
Infection

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. / Palladini, Giovanni; Milani, Paolo; Foli, Andrea; Basset, Marco; Russo, Francesca; Perlini, Stefano; Merlini, Giampaolo.

In: Blood, Vol. 129, No. 15, 13.04.2017, p. 2120-2123.

Research output: Contribution to journalArticle

@article{16fc2e350d02413f9ffaa11d1466f4c0,
title = "A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis",
abstract = "Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial,weassessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, alkylators, and other immunomodulatory drugs. Twenty-eight patients were enrolled. Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity. The remaining patients received 4mg/d. Pomalidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or 40 mg. Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and infection. Hematologic response was observed in 68{\%} of patients (very good partial response or complete response in 29{\%}), as well as improved survival. Median timetoresponsewas1month.PDexisarapidly active regimen and improves survival in responding, heavily pretreated patients with AL amyloidosis.",
author = "Giovanni Palladini and Paolo Milani and Andrea Foli and Marco Basset and Francesca Russo and Stefano Perlini and Giampaolo Merlini",
year = "2017",
month = "4",
day = "13",
doi = "10.1182/blood-2016-12-756528",
language = "English",
volume = "129",
pages = "2120--2123",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

AU - Palladini, Giovanni

AU - Milani, Paolo

AU - Foli, Andrea

AU - Basset, Marco

AU - Russo, Francesca

AU - Perlini, Stefano

AU - Merlini, Giampaolo

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial,weassessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, alkylators, and other immunomodulatory drugs. Twenty-eight patients were enrolled. Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity. The remaining patients received 4mg/d. Pomalidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or 40 mg. Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and infection. Hematologic response was observed in 68% of patients (very good partial response or complete response in 29%), as well as improved survival. Median timetoresponsewas1month.PDexisarapidly active regimen and improves survival in responding, heavily pretreated patients with AL amyloidosis.

AB - Immunomodulatory drugs are active agents in light-chain (AL) amyloidosis. However, previous studies could not show a survival advantage for patients with AL amyloidosis responding to salvage treatment with pomalidomide. In this phase 2 trial,weassessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with AL amyloidosis who were previously exposed to bortezomib, alkylators, and other immunomodulatory drugs. Twenty-eight patients were enrolled. Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity. The remaining patients received 4mg/d. Pomalidomide was administered continuously and dexamethasone was given once per week at a dose of 20 or 40 mg. Fifteen patients experienced grade 3 to 4 adverse events; the most common were fluid retention and infection. Hematologic response was observed in 68% of patients (very good partial response or complete response in 29%), as well as improved survival. Median timetoresponsewas1month.PDexisarapidly active regimen and improves survival in responding, heavily pretreated patients with AL amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=85018860409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018860409&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-12-756528

DO - 10.1182/blood-2016-12-756528

M3 - Article

C2 - 28130212

AN - SCOPUS:85018860409

VL - 129

SP - 2120

EP - 2123

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -